• Arthritis consists of more than 100 different conditions, the most common being osteoarthritis (degenerative joint disease), fibromyalgia, gout, and rheumatoid arthritis (also an autoimmune disease). The symptoms associated with arthritis are pain or tenderness in the joints, inflammation, and stiffness. Arthritis also causes breakdown of cartilage, which normally protects a joint, allowing it to move smoothly. When cartilage breaks down, bones rub together and create pain and inflammation. Arthritis can be acute or chronic. In the former case, the cause is found and treated or just goes away. In the latter case, the cause is never identified and a person lives for years or the rest of their lives with arthritis.

    The common symptoms of arthritis are:


    - Joint pain


    - Joint swelling


    - Reduced ability to move the joint


    - Redness of the skin around a joint


    - Stiffness, especially in the morning


    - Warmth around a joint


    Solutions include lifestyle changes, such as getting more low-impact aerobic exercise, range of motion exercises, sleeping 8 to 10 hours per night, changing the home to make activities easier, and eating healthier foods and foods rich in omega-3 fatty acids (which are prevalent in hemp oil). Physical therapy, massage, water therapy, and heat or ice are also beneficial.


    In animals, it has been found that "Cannabinoids have analgesic, immunomodulatory and anti-inflammatory properties and attenuate joint damage in animal models of arthritis" ("Arthritis and Cannabinoids: HU-210 and Win-55, 212-2 Prevent IL-1Alpha-Induced Matrix Degradation in Bovine Articular Chondrocytes In-Vitro," a study by the Biomedical Research Centre at Sheffield Hallam University in England). In another study, "Cannabinoids in the Management of Difficult to Treat Pain," conducted by the company GW Pharmaceuticals, states:


    Sativex ®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1) receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.


    These are compelling reports that show promise for treating arthritis with cannabinoids.


    http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002223/

  • Category
    Critical Ailments
  • Created
    Thursday, 16 March 2017
  • Group admin
    CBIS

American States University

 CSi_Updates_Outline2.jpgDrug Valuation Image3


 

 Recent GBXI News:

June 22, 2023, GBX International Group, Inc., (OTC: GBXI)
Breaking Cancer Barriers; Investments in Low-Cost, Harvard Award-Winning, Effective Cancer Killing Drugs Now; GBXI Proceeds to Raise $1 Million to Fast-Track its' Success, Cancer Drug Valuations, Access for Patients, Full Company Audit, and Accelerate the Trading of the CSi-Spinout Shares

 

May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets


April 21, 2023, GBX International Group, Inc., (OTC: GBXI)

HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans 



Harvard GHC Award RCD 2018

 

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

 

Click here to review the Report:

Frontiers Capture
1mmStrong July 8 Court UPDATE Brochure Image

Sac Court Capture

Case No. 2:17-CV-02271-KJM-JDP



Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB
 



Observational Studies

PART

Notifications

Activity Stream

Hi Raymond,

As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase...
Show more

Francis Cormier What I am waiting for is the Announcement for the Upcoming Public Fundraising Event reported previously; to be happening with a TBD date. I am... Show more 6 days ago
loader
loader
Attachment
RENE RAMIREZ How about a chart that shows action items with status and anticipated completion dates, yesterday
loader
loader
Attachment
grant r smith raymond - are the new shares that will be issued to us as each company comes online come to us before or after they start trading? 22 hours 10 minutes ago
loader
loader
Attachment
Raymond C. Dabney Great clarity question Grant, Thanks. As you see from the list there are several classes of shares on our Group:

1. Original CBIS, everyone has...
Show more
17 hours 8 minutes ago
loader
loader
Attachment
KELLY PINGSTERHAUS Thank you Raymond for the update. News and information is always welcome for it is all we get to see, whereas you see everything that is happening... Show more 15 hours 22 minutes ago
loader
loader
Attachment

Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"

HARVARD Award Winning 
CANCER Killing Success





1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

Frontiers_1.JPG


2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

 Frontiers_2.JPG


*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

WhatsApp_Image_2022-05-21_at_9.37.37_AM_3.jpg
Skin Cancer 

WhatsApp_Image_2022-05-21_at_9.37.38_AM.jpeg
Karposis Sarcoma

WhatsApp_Image_2022-05-21_at_9.37.38_AM_1.jpeg

CSi Final GIFT Share Issuance Nov 27 2022



Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

 LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

ASU/CSi-EDP-ECO-System
At it's FINEST !!! 

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.



2023 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2023

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296

Class A Common Stock
Authorized:
100,000,000
Issued:
0

Class B Common Stock
Authorized:
1,500,000,000
Issued:
0

Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000



Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE




*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!

 

Events

Sorry, we currently have no events.
View All Events